Your browser doesn't support javascript.
The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study.
Tien, Ni; Chang, Yu-Chang; Chen, Po-Ku; Lin, Hui-Ju; Chang, Shih-Hsin; Lan, Joung-Liang; Hsueh, Po-Ren; Chang, Ching-Kun; Chen, Der-Yuan.
  • Tien N; Department of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan.
  • Chang YC; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404, Taiwan.
  • Chen PK; Department of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan.
  • Lin HJ; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404, Taiwan.
  • Chang SH; College of Medicine, China Medical University, Taichung 404, Taiwan.
  • Lan JL; Rheumatology and Immunology Center, China Medical University Hospital, Taichung 404, Taiwan.
  • Hsueh PR; Translational Medicine Laboratory, Rheumatology and Immunology Center, China Medical University Hospital, Taichung 404, Taiwan.
  • Chang CK; Department of Laboratory Medicine, China Medical University Hospital, Taichung 404, Taiwan.
  • Chen DY; Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404, Taiwan.
Biomedicines ; 10(4)2022 Apr 15.
Article in English | MEDLINE | ID: covidwho-1792824
ABSTRACT
Patients with immune-mediated inflammatory diseases (IMID) were seldom enrolled in the studies of SARS-CoV-2 vaccines, and real-world data regarding the immunogenicity of different types of vaccines is limited. We aimed to assess the immunogenicity and safety of three types of vaccines (AZD1222, mRNA-1273, and BNT162b2) in 253 patients with IMID and 30 healthcare workers (HCWs). Plasma levels of IgG-antibody against SARS-CoV-2 targeting the receptor-binding domain of spike protein (anti-S/RBD-IgG) were determined by chemiluminescent immunoassay 3-4 weeks after the first-dose and second-dose vaccination. The positive rate and titers of anti-S/RBD-IgG were significantly higher in mRNA-1273 or BNT162b2 than in the AZD1222 vaccine. Immunogenicity was augmented after the second dose of any vaccine type in all IMID patients, suggesting that these patients should complete the vaccination series. Anti-S/RBD-IgG titers after first-dose vaccination were significantly lower in RA patients than pSS patients, but there was no significant difference after second-dose vaccination among five groups of IMID patients. The positive rate and titers of anti-S/RBD-IgG were significantly lower in patients receiving abatacept/rituximab therapy than in those receiving other DMARDs. All three SARS-CoV-2 vaccines showed acceptable safety profiles, and the common AEs were injection site reactions. We identified SLE as a significant predictor of increased autoimmunity and would like to promote awareness of the possibility of autoimmunity following vaccination.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10040911

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Biomedicines10040911